Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 21:32 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Prevention of Coronary Microvascular Dysfunction Post-PCI by Intracoronary Nicardipine
NCT03184155 · Thomas Jefferson University · EARLY_PHASE1 · withdrawn · last registry update 2024-04-26 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “This study was planned, but recruitment and enrollment never began.” | – | Registry record, Thomas Jefferson University |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CACNA1C within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2025-02-25Results posted on the registry: Stanford University, Nebivolol + Diltiazem (NCT04130438)
- 2025-02-25Also stopped (terminated): Stanford University, Nebivolol + Diltiazem (NCT04130438)
- 2025-02-06Results posted on the registry: Atrial Fibrillation Network, Edoxaban + ASA (NCT02618577)
- 2025-02-06Also stopped (terminated): Atrial Fibrillation Network, Edoxaban + ASA (NCT02618577)
- 2025-01-13Phase 3 first posted: CSPC ZhongQi Pharmaceutical Technology Co., Ltd., SYH9056 + Levamlodipine (NCT06771245)
- 2024-12-27Results posted on the registry: Corewell Health South, Oral + Intravenous drug (NCT05391893)
- 2024-12-05Phase 3 first posted: Rashid Latif Medical College, Adenosine + Verapamil Injection (NCT06717685)
- 2024-11-27Results posted on the registry: Jaeb Center for Health Research, verapamil 120mg tablet + placebo (NCT04233034)
- 2024-11-07Phase 3 first posted: Yonsei University, BP lowering drugs (nicardipine, labetalol, urapidil) + BP raising drug (phenylephrine) or BP lowering drugs (nicardipine, labetalol, urapidil) (NCT06677970)
- 2024-10-24Also stopped (withdrawn): Stephen Ruedrich, Valbenazine Oral Capsule (NCT06107829)
- 2024-05-03Results posted on the registry: Baylor Research Institute, a drug against CACNA1C (NCT04318990)
- 2024-02-23Phase 3 first posted: Oman Medical Speciality Board, Oral Bisoprolol + Intravenous Diltiazem (NCT06276127)
- 2023-11-27Results posted on the registry: BeiGene, Zanubrutinib + Fluconazole (NCT04551963)
- 2023-10-12Results posted on the registry: University of Cincinnati, Nicardipine + Labetalol (NCT04116112)
- 2023-07-18Also stopped (terminated): Seoul National University Hospital, Amiodarone, diltiazem or esmolol (NCT05950971)
- 2023-07-11Phase 3 first posted: Region Örebro County, dronedarone - Multaq™ OR flecainide - Tambocor™ OR propafenone - Rytmonorm™ OR sotalol - Sotacor™ (NCT05939076)
- 2023-05-26Also stopped (withdrawn): Hospices Civils de Lyon, DILTIAZEM TEVA 60 mg or placebo (NCT05563168)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision